Related Experiment Video

Updated: Oct 2, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy

Aleksandar Sikole1, Momir Polenakovic, Vera Spiroska

  • 1Department of Nephrology, Clinical Center, Medical Faculty, Vodnjanska, Skopje, Macedonia. asikole@freemail.org.mk

Artificial Organs
|March 7, 2002
PubMed

Insights

Erythropoietin (EPO) treatment in dialysis patients reversed left ventricular hypertrophy (LVH) by improving anemia. Stopping EPO therapy led to the return of LVH, indicating anemia

Area of Science:

  • Cardiology
  • Nephrology
  • Hematology

Background:

  • High cardiac output state is a primary driver of left ventricular hypertrophy (LVH).
  • Increased left ventricular mass is a significant predictor of morbidity and mortality.
  • Anemia is common in patients undergoing hemodialysis.

Purpose of the Study:

  • To investigate the impact of erythropoietin (EPO) therapy on left ventricular mass in hemodialysis patients.
  • To assess the reversibility of cardiac morphologic changes after EPO cessation.

Main Methods:

  • 14 hemodialysis patients with hematocrit <28% received subcutaneous EPO for 1 year.
  • Echocardiography was performed at baseline, 12 months, and 1 year post-EPO cessation.
  • Key cardiac parameters including left ventricular mass, end-diastolic volume, and cardiac output were measured.

Main Results:

  • EPO therapy significantly decreased left ventricular mass, end-diastolic volume, and cardiac output.
  • Total peripheral resistance and mean arterial pressure showed significant changes during EPO treatment.
  • Upon cessation of EPO, these cardiac parameters returned to baseline levels, indicating LVH reversibility.

Conclusions:

  • Erythropoietin therapy effectively reduces left ventricular hypertrophy in dialysis patients by correcting anemia.
  • Left ventricular hypertrophy in uremic patients is significantly influenced by anemia severity and is reversible.
  • Anemia management is crucial for mitigating cardiac remodeling in hemodialysis patients.

More Related Videos

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...